Clinical Trial Update: Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating neoadjuvant chemotherapy sequentially combined with Sintilimab in resectable EGFR-mutant non-small cell lung cancer; the study is not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING